• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脊髓小脑共济失调2型患者来源的诱导多能干细胞系H196的同基因、基因校正对照细胞系的产生。

Generation of an isogenic, gene-corrected control cell line of the spinocerebellar ataxia type 2 patient-derived iPSC line H196.

作者信息

Marthaler Adele G, Schmid Benjamin, Tubsuwan Alisa, Poulsen Ulla B, Engelbrecht Alexander F, Mau-Holzmann Ulrike A, Hyttel Poul, Nielsen Jørgen E, Nielsen Troels T, Holst Bjørn

机构信息

Department of Clinical and Veterinary Animal Science, Copenhagen University, Grønnegårdsvej 7, 1870 Frederiksberg C, Denmark; Neurogenetic Research Laboratory, Danish Dementia Research Centre, Department of Neurology, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Bioneer A/S, Kogle Allé 2, 2970 Hørsholm, Denmark.

出版信息

Stem Cell Res. 2016 Jan;16(1):162-5. doi: 10.1016/j.scr.2015.12.031. Epub 2016 Jan 3.

DOI:10.1016/j.scr.2015.12.031
PMID:27345804
Abstract

Spinocerebellar ataxia type 2 (SCA2) is a neurodegenerative disease primarily affecting the cerebellum. Very little is known about the molecular mechanisms underlying the disease and, to date, no cure or treatment is available. We have successfully generated bona fide induced pluripotent stem cell (iPSC) lines of SCA2 patients in order to study a disease-specific phenotype. Here, we demonstrate the gene correction of the iPSC line H196 clone 7 where we have exchanged the expanded CAG repeat of the ATXN2 gene with the normal length found in healthy alleles. This gene corrected cell line will provide the ideal control to model SCA2 by iPSC technology.

摘要

2型脊髓小脑共济失调(SCA2)是一种主要影响小脑的神经退行性疾病。对于该疾病的潜在分子机制知之甚少,迄今为止,尚无治愈方法或治疗手段。为了研究疾病特异性表型,我们成功建立了SCA2患者的真正诱导多能干细胞(iPSC)系。在此,我们展示了iPSC系H196克隆7的基因校正,其中我们已将ATXN2基因的扩展CAG重复序列替换为健康等位基因中发现的正常长度。这种基因校正的细胞系将为通过iPSC技术模拟SCA2提供理想的对照。

相似文献

1
Generation of an isogenic, gene-corrected control cell line of the spinocerebellar ataxia type 2 patient-derived iPSC line H196.脊髓小脑共济失调2型患者来源的诱导多能干细胞系H196的同基因、基因校正对照细胞系的产生。
Stem Cell Res. 2016 Jan;16(1):162-5. doi: 10.1016/j.scr.2015.12.031. Epub 2016 Jan 3.
2
Generation of an isogenic, gene-corrected control cell line of the spinocerebellar ataxia type 2 patient-derived iPSC line H266.生成脊髓小脑共济失调2型患者来源的诱导多能干细胞系H266的同基因、基因校正对照细胞系。
Stem Cell Res. 2016 Jan;16(1):202-5. doi: 10.1016/j.scr.2015.12.048. Epub 2016 Jan 15.
3
Generation of an isogenic, gene-corrected control cell line of the spinocerebellar ataxia type 2 patient-derived iPSC line H271.
Stem Cell Res. 2016 Jan;16(1):180-3. doi: 10.1016/j.scr.2015.12.028. Epub 2016 Jan 3.
4
Generation of spinocerebellar ataxia type 2 patient-derived iPSC line H196.2型脊髓小脑共济失调患者来源的诱导多能干细胞系H196的产生
Stem Cell Res. 2016 Jan;16(1):199-201. doi: 10.1016/j.scr.2015.12.049. Epub 2016 Jan 15.
5
Generation of spinocerebellar ataxia type 2 patient-derived iPSC line H271.2型脊髓小脑共济失调患者来源的诱导多能干细胞系H271的产生。
Stem Cell Res. 2016 Jan;16(1):159-61. doi: 10.1016/j.scr.2015.12.027. Epub 2016 Jan 3.
6
Generation of spinocerebellar ataxia type 2 patient-derived iPSC line H266.2型脊髓小脑共济失调患者来源的诱导多能干细胞系H266的生成。
Stem Cell Res. 2016 Jan;16(1):166-9. doi: 10.1016/j.scr.2015.12.029. Epub 2016 Jan 3.
7
Generation of human-induced pluripotent stem cells to model spinocerebellar ataxia type 2 in vitro.体外生成人类诱导多能干细胞模型以模拟脊髓小脑共济失调 2 型。
J Mol Neurosci. 2013 Oct;51(2):237-48. doi: 10.1007/s12031-012-9930-2. Epub 2012 Dec 9.
8
Generation of Spinocerebellar Ataxia Type 2 induced pluripotent stem cell lines, CHOPi002-A and CHOPi003-A, from patients with abnormal CAG repeats in the coding region of the ATXN2 gene.从ATXN2基因编码区CAG重复序列异常的患者中生成2型脊髓小脑共济失调诱导多能干细胞系CHOPi002 - A和CHOPi003 - A。
Stem Cell Res. 2019 Jan;34:101361. doi: 10.1016/j.scr.2018.101361. Epub 2018 Dec 10.
9
Generation of a gene-corrected isogenic control cell line from an Alzheimer's disease patient iPSC line carrying a A79V mutation in PSEN1.从携带PSEN1基因A79V突变的阿尔茨海默病患者诱导多能干细胞系中生成基因校正的同基因对照细胞系。
Stem Cell Res. 2016 Sep;17(2):285-288. doi: 10.1016/j.scr.2016.08.002. Epub 2016 Aug 7.
10
Generation of an isogenic, gene-corrected iPSC line from a symptomatic 59-year-old female patient with frontotemporal dementia caused by an R406W mutation in the microtubule associated protein tau (MAPT) gene.从一名患有额颞叶痴呆的59岁有症状女性患者中生成了一个等基因、基因校正的诱导多能干细胞系,该患者的额颞叶痴呆由微管相关蛋白tau(MAPT)基因中的R406W突变引起。
Stem Cell Res. 2016 Nov;17(3):576-579. doi: 10.1016/j.scr.2016.09.020. Epub 2016 Sep 28.

引用本文的文献

1
Roots of Progress: Uncovering Cerebellar Ataxias Using iPSC Models.进步的根源:利用诱导多能干细胞模型揭示小脑共济失调
Biomedicines. 2025 Aug 30;13(9):2121. doi: 10.3390/biomedicines13092121.
2
A comprehensive review of iPS cell line-based disease modelling of the polyglutamine spinocerebellar ataxias 2 and 3: a focus on the research outcomes.基于诱导多能干细胞系的多聚谷氨酰胺脊髓小脑共济失调2型和3型疾病建模的综合综述:聚焦研究成果
Ann Med Surg (Lond). 2024 Mar 19;86(6):3487-3498. doi: 10.1097/MS9.0000000000001984. eCollection 2024 Jun.
3
Recent Advances in CRISPR/Cas9 Delivery Approaches for Therapeutic Gene Editing of Stem Cells.
CRISPR/Cas9 递送方法在干细胞治疗性基因编辑中的最新进展。
Stem Cell Rev Rep. 2023 Nov;19(8):2576-2596. doi: 10.1007/s12015-023-10585-3. Epub 2023 Sep 18.
4
Advances in Modeling Polyglutamine Diseases Using Genome Editing Tools.利用基因组编辑工具研究多聚谷氨酰胺疾病的进展。
Cells. 2022 Feb 2;11(3):517. doi: 10.3390/cells11030517.
5
Current and emerging treatment modalities for spinocerebellar ataxias.脊髓小脑共济失调的当前和新兴治疗方法。
Expert Rev Neurother. 2022 Feb;22(2):101-114. doi: 10.1080/14737175.2022.2029703. Epub 2022 Feb 10.
6
Human Induced Pluripotent Stem Cell-Based Modelling of Spinocerebellar Ataxias.基于人诱导多能干细胞的脊髓小脑共济失调建模。
Stem Cell Rev Rep. 2022 Feb;18(2):441-456. doi: 10.1007/s12015-021-10184-0. Epub 2021 May 25.
7
Targeted Oligonucleotides for Treating Neurodegenerative Tandem Repeat Diseases.靶向寡核苷酸治疗神经退行性串联重复疾病。
Neurotherapeutics. 2019 Apr;16(2):248-262. doi: 10.1007/s13311-019-00712-9.
8
Next Generation Precision Medicine: CRISPR-mediated Genome Editing for the Treatment of Neurodegenerative Disorders.下一代精准医学:CRISPR 介导的基因组编辑治疗神经退行性疾病。
J Neuroimmune Pharmacol. 2019 Dec;14(4):608-641. doi: 10.1007/s11481-019-09849-y. Epub 2019 Apr 23.
9
CRISPR-cas gene-editing as plausible treatment of neuromuscular and nucleotide-repeat-expansion diseases: A systematic review.CRISPR-cas 基因编辑作为治疗神经肌肉和核苷酸重复扩展疾病的合理方法:系统评价。
PLoS One. 2019 Feb 22;14(2):e0212198. doi: 10.1371/journal.pone.0212198. eCollection 2019.
10
Recapitulating and Correcting Marfan Syndrome in a Cellular Model.在细胞模型中重现并纠正马凡综合征
Int J Biol Sci. 2017 Apr 10;13(5):588-603. doi: 10.7150/ijbs.19517. eCollection 2017.